More articles about NASDAQ:OREX | Wall St. Cheat Sheet

March 17, 2013

These Drug Makers Are Letting Growth Opportunities Slide By

Several healthcare companies have allowed growth opportunities slide between their fingers...

March 14, 2013

Will Arena Pharmaceuticals Move Higher?

If Arena is able to create a profitable product, the company is poised to see excellent returns. Investors have been mixed about the last four earnings announcements and it shows in their relative performance...

March 13, 2013

Is Vivus a Worthwhile Risk?

Vivus has performed poorly over the past year. Is this trend likely to continue?

March 11, 2013

Which White-Hot Drug Stocks Have the Strongest Earnings Trends?

A combination of earnings strength and relative strength against competitors is a recipe for success...

March 01, 2013

Which of These 4 White Hot Drug Stocks Have the Strongest Earnings Trends?

A combination of earnings strength and relative strength against competitors is a recipe for success...

January 28, 2013

Oracle’s Hardware Business Predicted to Rebound and 4 Stock Analyses Sparking Chatter

Here's what analysts had to say about these companies today...

January 18, 2013

Vivus Plunges on Downgrade, Johnson & Johnson Ties Up Loose Ends, Pfizer Initiates a Spin-Off

Shares of Johnson & Johnson, Pfizer, and Vivus are all on the move on Friday...

January 17, 2013

Vivus’s Weightloss Drug is a Flop and 2 Hot Healthcare Stocks to Watch

Shares of UnitedHealth, Intuitive Surgical, and Vivus are all on the move on Wednesday...

January 07, 2013

Will Vivus’s Weight-Loss Drug Fall Flat?

Qsymia sales only generated $41,000 in the company’s third quarter, representing 656 filled prescriptions. But on Monday, Vivus reported that sales of its main product rose close to 68 percent in the month ended December 21, which was well above analysts' expectations...